H146
4-羟基美芬妥英
≥98% (HPLC)
别名:
(±)-5-乙基-5-(4-羟苯基)-3-甲基海因, (±)-5-乙基-5-(4-羟苯基)-3-甲基羟基香豆素-2,4-二酮
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C12H14N2O3
化学文摘社编号:
分子量:
234.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
solubility
DMSO: >5 mg/mL
SMILES string
CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2
InChI
1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)
InChI key
OQPLORUDZLXXPD-UHFFFAOYSA-N
General description
美芬妥英的 YP2C19 代谢物。
Application
药理活性研究：
用于电子捕获气相色谱法的分析物
- 药物对代谢的影响
- 体外微粒体细胞色素P450活性
用于电子捕获气相色谱法的分析物
Still not finding the right product?
Explore all of our products under 4-羟基美芬妥英
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
J K Coller et al.
British journal of clinical pharmacology, 48(2), 158-167 (1999-07-27)
To compare the oxidative metabolism of (S)-mephenytoin and proguanil in vitro and to determine the involvement of various cytochrome P450 isoforms. The kinetics of the formation of 4'-hydroxymephenytoin and cycloguanil in human liver microsomes from 10 liver samples were determined
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| H146-5MG | 04061833665596 |
| SAB4200219-200UL | 04061836270582 |